Khaled Hammoud, MD
Neurology · Lafayette, INNPI 1982806402
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Argenx US, Inc. at 39.8% of the total. 2025 is the largest year on record at $14,946, 3.8 times the $3,960 reported in 2019.
Across 927 payments — averaging $32.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$12K
- AbbVie$2K
- Livanova USA, Inc.$2K
- Biogen$989
- Medtronic$911
- Novartis$699
- plus $11K from 54 others
Across 3 payments — averaging $8324.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$25K
What the payments were for
- Consulting fees$1500%
- Speaking & faculty fees$11,01736%
- Travel & lodging$1,9987%
- Food & beverage$17,19756%
- Education$1160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,477 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 37 | $356,915 |
| IngrezzaValbenazine Tosylate | 35 | $281,129 |
| Kesimpta PenOfatumumab | 21 | $214,492 |
| XywavSodium,calcium,mag,pot Oxybate | 13 | $201,115 |
| NuplazidPimavanserin Tartrate | 13 | $144,207 |
| BotoxOnabotulinumtoxina | 91 | $117,440 |
| FingolimodFingolimod Hcl | 17 | $104,485 |
| EpidiolexCannabidiol (Cbd) | 23 | $85,151 |
| GocovriAmantadine Hcl | 13 | $78,199 |
| Nurtec OdtRimegepant Sulfate | 52 | $60,391 |
| Emgality PenGalcanezumab-Gnlm | 45 | $45,082 |
| QuliptaAtogepant | 34 | $42,687 |
| BriviactBrivaracetam | 31 | $42,027 |
| AptiomEslicarbazepine Acetate | 16 | $40,012 |
| UbrelvyUbrogepant | 34 | $36,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $474 | $356,91537 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $214 | $281,12935 claims |
| AbbVieBotox, Qulipta, Ubrelvy, Namzaric | $2,214 | $207,026171 claims |
| Acadia Pharmaceuticals IncNuplazid | $509 | $144,20713 claims |
| PfizerNurtec Odt, Eliquis | $574 | $84,05494 claims |
| MDD US Operations, LLCGocovri | $338 | $78,19913 claims |
| UCB, Inc.Briviact | $389 | $42,02731 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $450 | $40,01216 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $248 | $29,78317 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $234 | $23,76935 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $344 | $20,17396 claims |
| SK Life Science, Inc.Xcopri | $317 | $16,77416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.
Other neurology in Lafayette
- Anthony SimchakLafayette$720K
- William ConteMerrillville$1.2M
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
- Marlene BultemeyerFort Wayne$277K
- Jerry SmarttCarmel$254K
- Andrea HallerFort Wayne$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.